Adaptive Biotechnologies Corp
adaptivebiotech.comAdaptive Biotechnologies Corp (NASDAQ: ADPT) is a biotechnology company that uses its immune medicine platform to decode the adaptive immune system for disease detection and treatment applications. Revenue comes from two reported segments: MRD (minimal residual disease) testing for blood cancers and immune medicine research services. The MRD segment generates clinical testing revenue by processing patient samples through its clonoSEQ assay, an FDA-cleared test used to monitor certain blood cancers. The immune medicine segment has historically included collaboration revenue, most notably from a now-terminated agreement with Genentech. Adaptive was founded in 2009 and is headquartered in Seattle, Washington. The filing covering fiscal year ended December 31, 2025 references restructuring activity, impairment of long-lived assets, and an adjusted EBITDA non-GAAP metric, indicating the company has not reached GAAP profitability. The termination of the Genentech agreement is disclosed as a material event affecting the composition of revenue going forward.
Products & Services
clonoSEQ assay (FDA-cleared minimal residual disease test for blood cancers); immune medicine research and collaboration services.
Revenue Model
Clinical testing fees from the clonoSEQ MRD assay and collaboration or research services revenue from immune medicine partnerships, including a now-terminated Genentech agreement, as reported in the 10-K filed 2026-02-26 for FY2025.
Customers & Markets
Oncology clinicians and hospitals ordering MRD testing for blood cancer patients; biopharmaceutical partners for immune medicine research collaborations.
Geographic Exposure
Filing does not provide a breakdown of geographic revenue in the excerpts provided.
Financial Snapshot
Loading...
